Abstract
Background: Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer, which is the leading cause of death worldwide with the majority of patients presenting with advanced disease at the time of diagnosis.
Objective: In this review, the emergence of erlotinib as a seed for the treatment of NSCLC has been discussed and how it is gaining limelight as one of the most suitable drugs for this indication. The approval status in different regions and recommendation data from Health Technology Assessment (HTA) agencies like National Institute for Care and Excellence (NICE), UK and Wales and Scottish Medical Consortium (SMC), Scotland have also been collected in this study.
Method: For carrying out the review, literature was searched on various databases including PubMed, Clinicaltrial.gov, various HTA databases, EMBASE, Google Scholar, United States Food and Drugs Administration (USFDA) and various other online databases. Information from these sources was compared and analyzed as per the requirement of the objective.
Results: From the literature obtained after searching various databases, it was observed that Erlotinib (Tarceva) is one of the drugs which acts on EGFR and was approved (2004) from USFDA for treating locally advanced or metastatic NSCLC, as second or third line treatment after the failure of chemotherapy regimen. Different Health Technology Assessment (HTA) agencies have also assessed erlotinib for various indications and have given guidance for its use.
Conclusion: On the basis of available literature and data on clinical studies, it can be concluded that erlotinib can be the better option for treatment of NSCLC and effective against different lines of treatment and in maintenance as well.
Keywords: Erlotinib, non-small cell lung cancer, clinical trials, health technology assessment agencies, epidermal growth factor receptor, EGFR.
Graphical Abstract
Clinical Cancer Drugs
Title:Erlotinib in Non-Small Cell Lung Cancer: From a thought to Necessity
Volume: 5
Author(s): Parijat Pandey and Harish Dureja*
Affiliation:
- Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak, 124001,India
Keywords: Erlotinib, non-small cell lung cancer, clinical trials, health technology assessment agencies, epidermal growth factor receptor, EGFR.
Abstract: Background: Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer, which is the leading cause of death worldwide with the majority of patients presenting with advanced disease at the time of diagnosis.
Objective: In this review, the emergence of erlotinib as a seed for the treatment of NSCLC has been discussed and how it is gaining limelight as one of the most suitable drugs for this indication. The approval status in different regions and recommendation data from Health Technology Assessment (HTA) agencies like National Institute for Care and Excellence (NICE), UK and Wales and Scottish Medical Consortium (SMC), Scotland have also been collected in this study.
Method: For carrying out the review, literature was searched on various databases including PubMed, Clinicaltrial.gov, various HTA databases, EMBASE, Google Scholar, United States Food and Drugs Administration (USFDA) and various other online databases. Information from these sources was compared and analyzed as per the requirement of the objective.
Results: From the literature obtained after searching various databases, it was observed that Erlotinib (Tarceva) is one of the drugs which acts on EGFR and was approved (2004) from USFDA for treating locally advanced or metastatic NSCLC, as second or third line treatment after the failure of chemotherapy regimen. Different Health Technology Assessment (HTA) agencies have also assessed erlotinib for various indications and have given guidance for its use.
Conclusion: On the basis of available literature and data on clinical studies, it can be concluded that erlotinib can be the better option for treatment of NSCLC and effective against different lines of treatment and in maintenance as well.
Export Options
About this article
Cite this article as:
Pandey Parijat and Dureja Harish *, Erlotinib in Non-Small Cell Lung Cancer: From a thought to Necessity, Clinical Cancer Drugs 2018; 5 (2) . https://dx.doi.org/10.2174/2212697X06666190102110412
DOI https://dx.doi.org/10.2174/2212697X06666190102110412 |
Print ISSN 2212-697X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-6988 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Collateral Damage Control in Cancer Therapy: Defining the Stem Identity in Gliomas
Current Pharmaceutical Design Beneficial and Adverse Effects of Molecularly Targeted Therapies for Acute Promyelocytic Leukemia in Central Nervous System
CNS & Neurological Disorders - Drug Targets Computational Methods and Algorithms for Mass-Spectrometry Based Differential Proteomics
Current Proteomics Anticancer and Antibacterial Activity of Hyperforin and Its Derivatives
Anti-Cancer Agents in Medicinal Chemistry Humoral Immunity in HIV-1 Exposure: Cause or Effect of HIV Resistance?
Current HIV Research Novel non-invasive Adjunctive Techniques for Early Oral Cancer Diagnosis and Oral Lesions Examination
Current Pharmaceutical Design Novel Approaches for Molecular Targeted Therapy of Breast Cancer: Interfering with PI3K/AKT/mTOR Signaling
Current Cancer Drug Targets Roles of EGFR, PI3K, AKT, and mTOR in Heavy Metal-Induced Cancer
Current Cancer Drug Targets Mechanisms of Action of DNA-Damaging Anticancer Drugs in Treatment of Carcinomas: Is Acute Apoptosis an “Off-Target” Effect?
Mini-Reviews in Medicinal Chemistry Simple C-2-Substituted Quinolines and their Anticancer Activity
Letters in Drug Design & Discovery Cytotoxic Properties of Clofibrate and other Peroxisome Proliferators: Relevance to Cancer Progression
Current Medicinal Chemistry Gallium-68 in Medical Imaging
Current Radiopharmaceuticals Exploiting Protein Phosphatase Inhibitors Based on Cantharidin Analogues for Cancer Drug Discovery
Mini-Reviews in Medicinal Chemistry Viruses in Semen and Male Genital Tissues - Consequences for the Reproductive System and Therapeutic Perspectives
Current Pharmaceutical Design α(N)-Heterocyclic Thiosemicarbazones: Iron Chelators that are Promising for Revival of Gallium in Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Physiologically Based Mathematical Models to Optimize Therapies Against Metastatic Colorectal Cancer: A Mini-Review
Current Pharmaceutical Design Exploring Old Drugs for the Treatment of Hematological Malignancies
Current Medicinal Chemistry MEK Inhibitors: A Therapeutic Approach to Targeting the Ras-MAP Kinase Pathway in Tumors
Current Pharmaceutical Design Effects of Oxymatrine from Ku Shen on Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry An Unbiased Predictive Model to Detect DNA Methylation Propensity of CpG Islands in the Human Genome
Current Bioinformatics